Ticker > Company >

Samrat Pharmachem share price

Samrat Pharmachem Ltd.

BSE: 530125 SECTOR: Pharmaceuticals & Drugs  23.14 K   136   14

324.95
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 325

Today's Low

₹ 315.15

52 Week High

₹ 646

52 Week Low

₹ 302.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

100.4 Cr.

Enterprise Value

99.13 Cr.

No. of Shares

0.31 Cr.

P/E

20.84

P/B

1.4

Face Value

₹ 10

Div. Yield

0.31 %

Book Value (TTM)

₹  231.64

CASH

9.73 Cr.

DEBT

8.45 Cr.

Promoter Holding

49.09 %

EPS (TTM)

₹  15.59

Sales Growth

-9.36%

ROE

3.38 %

ROCE

4.13%

Profit Growth

-87 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-9.36%
3 Year16.3%
5 Year20.43%

Profit Growth

1 Year-87%
3 Year-25.98%
5 Year7.09%

ROE%

1 Year3.38%
3 Year26.19%
5 Year23.49%

ROCE %

1 Year4.13%
3 Year30.46%
5 Year27.54%

Debt/Equity

0.1301

Price to Cash Flow

10.67

Interest Cover Ratio

4.6684

CFO/PAT (5 Yr. Avg.)

0.459319151535634

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 49.09 0.00
Mar 2025 49.09 0.00
Dec 2024 49.09 0.00
Sep 2024 48.95 0.00
Jun 2024 48.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 16.2969944005669% for the Past 3 years.
  • The company has significantly decreased its debt by 10.2046 Cr.
  • The company has an efficient Cash Conversion Cycle of 59.1702 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.60006533457187.

 Limitations

  • The company has shown a poor profit growth of -25.9833469764689% for the Past 3 years.
  • The company is trading at a high PE of 20.84.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 80.82 70.17 63.66 71.2 75.65
Total Expenditure 78.24 66.81 59.49 71.08 75.53
Operating Profit 2.59 3.36 4.17 0.13 0.13
Other Income 0.59 0.49 0 -0.11 0.69
Interest 0.19 0.17 0.1 0.22 0.44
Depreciation 0.16 0.17 0.17 0.16 0.17
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.82 3.52 3.91 -0.36 0.21
Tax 0.75 0.86 1.13 0.04 0.44
Profit After Tax 2.07 2.66 2.79 -0.4 -0.23
Adjusted EPS (Rs) 6.69 8.61 9.01 -1.29 -0.74

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 137.45 179.02 221.75 310.65 281.58
Total Expenditure 130.82 170.35 197.51 286.72 279.11
Operating Profit 6.63 8.67 24.24 23.93 2.47
Other Income 0.57 0.46 0.63 0.48 1.38
Interest 0.98 1.28 0.67 1.23 0.69
Depreciation 0.43 0.49 0.59 0.64 0.65
Exceptional Items -0.01 -0.02 0 0 0
Profit Before Tax 5.78 7.34 23.6 22.53 2.52
Tax 1.55 2.01 6.42 5.9 0.36
Net Profit 4.24 5.33 17.18 16.63 2.16
Adjusted EPS (Rs.) 13.71 17.26 55.62 53.83 7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 3.09 3.09 3.09 3.09 3.09
Total Reserves 21.21 26.55 43.73 60.05 61.91
Borrowings 0 0 0 0 0
Other N/C liabilities 0.14 0.43 0.46 0.25 0.34
Current liabilities 33.9 27.33 37.33 53.19 56.4
Total Liabilities 58.35 57.4 84.61 116.59 121.74
Assets
Net Block 7.19 9.4 9.99 10.7 10.72
Capital WIP 1.08 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 1.86 2.92
Loans & Advances 0.4 0.65 0.8 0.91 1.47
Other N/C Assets 0 0.02 2.56 4.06 4.06
Current Assets 49.68 47.32 71.26 99.05 102.57
Total Assets 58.35 57.4 84.61 116.59 121.74
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 5.79 7.34 23.6 22.53 2.52
Adjustment 1.39 1.7 1.19 1.65 0.03
Changes in Assets & Liabilities -7.62 -1.99 -5.78 -24.12 9.27
Tax Paid -0.87 -2.25 -1.53 -9.5 -2.41
Operating Cash Flow -1.33 4.8 17.47 -9.44 9.41
Investing Cash Flow -1.92 -2.92 -1.06 -3 -0.41
Financing Cash Flow 2 -1.89 -1.95 9.6 -11.2
Net Cash Flow -1.25 -0.02 14.46 -2.84 -2.19

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 48.64 48.95 49.09 49.09 49.09
falguni kaushal mehta 2.15 2.15 2.15 2.15 2.15
jaya lalit mehta 3.86 3.86 3.86 3.86 3.86
kalpana premal mehta 1.64 1.64 1.64 1.64 1.64
kaushal lalit mehta 4.50 4.50 4.50 4.50 4.50
lalit damodar mehta 13.97 13.97 13.97 13.97 13.97
maitri megh mehta 0.27 0.38 0.47 0.47 0.47
megh rajesh mehta 1.51 1.71 1.76 1.76 1.76
premal lalit mehta 5.67 5.67 5.67 5.67 5.67
rajesh lalit mehta 12.41 12.41 12.41 12.41 12.41
rupal rajesh mehta 2.66 2.66 2.66 2.66 2.66
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 51.36 51.05 50.91 50.91 50.91
anshul specialty molecule... 1.31 1.31 1.31 1.31 1.31
lalit kumar v jain - 1.09 1.22 1.22 1.22
lloyds securities oversea... 3.24 3.24 3.24 3.24 3.24
llp 0.04 0.05 0.01 0.01 0.01
sangeetha s 3.27 3.27 3.27 3.27 3.27
sharad kanayalal shah 1.13 1.13 1.13 1.13 1.13

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Samrat Pharmachem - Quaterly Results 13 Aug, 9:12 PM Samrat Pharmachem - Quaterly Results 13 Aug, 9:12 PM Samrat Pharmachem informs about certificate 18 Jul, 5:24 PM Samrat Pharmachem informs about change in management 16 Jul, 4:50 PM Samrat Pharmachem informs about credit rating 3 Jun, 5:57 PM Samrat Pharmachem informs about integrated filing 4 Mar, 4:48 PM Samrat Pharmachem - Quaterly Results 14 Feb, 3:42 PM Samrat Pharmachem informs about newspaper publication 23 Aug, 4:12 PM Samrat Pharmachem - Quaterly Results 13 Aug, 5:16 PM Samrat Pharmachem - Quaterly Results 13 Aug, 5:16 PM Samrat Pharmachem informs about newspaper advertisement 3 Jun, 5:29 PM Samrat Pharmachem - Quaterly Results 14 Feb, 4:06 PM Samrat Pharmachem - Quaterly Results 14 Feb, 4:06 PM Samrat Pharmachem informs about newspapers advertisement 23 Nov, 5:20 PM Samrat Pharmachem informs about press release 18 Sep, 5:08 PM Samrat Pharmachem informs about record date for dividend payment 8 Sep, 5:16 PM Samrat Pharmachem - Quaterly Results 14 Aug, 3:57 PM Samrat Pharmachem informs about loss of share certificates 9 Aug, 3:14 PM Samrat Pharmachem informs about issuance of duplicate share certificates 24 Jul, 5:12 PM Samrat Pharmachem informs about issuance of duplicate share certificate 22 May, 12:32 PM Samrat Pharmachem informs about non-applicability of large corporate entity 10 May, 3:07 PM Samrat Pharmachem informs about certificate 12 Apr, 4:05 PM Samrat Pharmachem informs about issuance of duplicate share certificate 3 Apr, 4:46 PM Samrat Pharmachem informs about trading window closure 28 Mar, 4:47 PM Samrat Pharmachem informs about loss of share certificate 24 Mar, 4:38 PM Samrat Pharmachem informs about issuance of duplicate certificate 30 Jan, 5:23 PM Samrat Pharmachem - Quaterly Results 14 Nov, 3:32 PM Samrat Pharmachem informs about compliance certificate 12 Oct, 5:11 PM Samrat Pharmachem informs about outcome of AGM 3 Oct, 4:54 PM Samrat Pharmachem informs about approval of un-audited financial results 10 Feb, 5:00 PM Samrat Pharmachem - Quaterly Results 10 Feb, 3:41 PM Samrat Pharmachem - Quaterly Results 10 Feb, 3:41 PM Samrat Pharmachem - Quaterly Results 10 Feb, 3:41 PM Samrat Pharmachem informs about newspaper publication 19 Nov, 1:37 PM Samrat Pharmachem informs about newspaper advertisement 17 Feb, 4:20 PM Samrat Pharmachem informs about newspaper publication 24 Dec, 3:15 PM

Samrat Pharmachem Stock Price Analysis and Quick Research Report. Is Samrat Pharmachem an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Samrat Pharmachem. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Samrat Pharmachem has a PE ratio of 20.8385437708818 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Samrat Pharmachem has ROA of 1.8148% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Samrat Pharmachem has a Current ratio of 1.8185.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Samrat Pharmachem has a ROE of 3.3754%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Samrat Pharmachem has a Debt to Equity ratio of 0.1301 which means that the company has low proportion of debt in its capital.

  • Sales growth: Samrat Pharmachem has reported revenue growth of -9.3562% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Samrat Pharmachem for the current financial year is 0.877011675495375%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Samrat Pharmachem is Rs 1 and the yield is 0.3077%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Samrat Pharmachem is Rs 15.5937. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Samrat Pharmachem in Ticker for free. Also, one can get the intrinsic value of Samrat Pharmachem by using Valuation Calculators, which are available with a Finology ONE subscription. 

Samrat Pharmachem FAQs

Q1. What is Samrat Pharmachem share price today?
Ans: The current share price of Samrat Pharmachem is Rs 324.95.

Q2. What is the market capitalisation of Samrat Pharmachem?
Ans: Samrat Pharmachem has a market capitalisation of Rs 100.3998015 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Samrat Pharmachem?
Ans: The PE ratio of Samrat Pharmachem is 20.8385437708818 and the P/B ratio of Samrat Pharmachem is 1.40280578424808, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Samrat Pharmachem share?
Ans: The 52-week high share price of Samrat Pharmachem is Rs 646, and the 52-week low share price of Samrat Pharmachem is Rs 302.05.

Q5. Does Samrat Pharmachem pay dividends?
Ans: Currently, Samrat Pharmachem pays dividends. Dividend yield of Samrat Pharmachem is around 0.3077%.

Q6. What are the face value and book value of Samrat Pharmachem shares?
Ans: The face value of Samrat Pharmachem shares is Rs 10, while the book value per share of Samrat Pharmachem is around Rs 231.6429. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Samrat Pharmachem?
Ans: Samrat Pharmachem has a total debt of Rs 8.4547 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Samrat Pharmachem?
Ans: The ROE of Samrat Pharmachem is 3.3754% and ROCE of Samrat Pharmachem is 4.1315%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Samrat Pharmachem a good buy for the long term?
Ans: The Samrat Pharmachem long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Samrat Pharmachem undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Samrat Pharmachem appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Samrat Pharmachem’s financials?
Ans: You can review Samrat Pharmachem’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Samrat Pharmachem
X